Christopher David Hinojosa

Cambridge, MA, United States of America

Christopher David Hinojosa

This inventor holds 66 USPTO granted patents and 20 published patent applications, plus 13 CIPO patents and 8 EPO patents, primarily in Microfluidic Devices (CPC class B01L). Top assignees: Emulate, Inc., Harvard College, Cedars-Sinai Medical Center. Active years: 2017-2025. Education: Portland State University (USA).

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher David Hinojosa. Retrieved from https://idiyas.com/inventor/christopher-david-hinojosa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Graduated from:
  • Portland State University (USA)
USPTO Granted Patents = 66 

% Patents Active = 98.5

 

 

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 94(Granted Patents)

Forward Citations (Not Self Cited) = 45(Dec 10, 2025)



Location History:

  • Cambridge, MA (US) (2017 - 2024)
  • Malden, MA (US) (2019 - 2024)

Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Microfluidic Control
Organ-On-Chip
Cell Culture
Blood Brain Barrier
Intestinal Cells
Pressure Control
Osteogenic Differentiation
Low Shear Devices
Gas Mixer
Fluidic Interconnection
Dynamic Permeability
Microphysiological Systems
66 patents (USPTO):Explore Patents

Sure, here is an article about inventor Christopher David Hinojosa:

Title: Innovator Spotlight: Christopher David Hinojosa

Introduction:

Christopher David Hinojosa is a prolific inventor based in Cambridge, MA, with an impressive portfolio of 53 patents to his name. His innovative work in the field of microfluidic devices has revolutionized the way we culture living cells for modeling physiological functions of tissues and organs.

Latest Patents:

One of his latest patents includes "Systems and methods for growth of intestinal cells in microfluidic devices." This patent focuses on using Organs-on-chips, microfluidic devices that culture living cells in chambers to mimic physiological functions. By incorporating iPSC-derived epithelium, including patient-specific cells, Hinojosa's innovation allows for superior disease modeling of conditions like inflammatory bowel diseases.

Another notable patent is "Low shear microfluidic devices and methods of use and manufacturing thereof." This patent introduces systems for producing stratified structures with central channels divided into mesochannels and microchannels. These systems support the growth and differentiation of primary cells like human lung cells and enable the simulation of microenvironments for studying physiology, disease states, and identifying therapeutic agents.

Career Highlights:

Christopher David Hinojosa has made significant contributions during his tenure at Emulate, Inc. and the President and Fellows of Harvard College. His dedication to advancing technology in the field of microfluidic devices has positioned him as a leader in the industry.

Collaborations:

Throughout his career, Hinojosa has collaborated closely with colleagues such as Daniel Levner and Joshua Gomes. These collaborations have led to groundbreaking inventions that have the potential to impact various fields, from healthcare to drug development.

Conclusion:

In conclusion, Christopher David Hinojosa's innovative work in the development of microfluidic devices showcases his commitment to advancing scientific research and improving disease modeling. His patents reflect a deep understanding of cellular biology and a passion for creating cutting-edge solutions in the field of tissue engineering. Hinojosa's contributions continue to shape the future of healthcare and biotechnology, making him a standout figure in the world of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…